IFG Advisory LLC acquired a new position in Johnson & Johnson (NYSE:JNJ) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 46,077 shares of the company’s stock, valued at approximately $3,405,000. Johnson & Johnson comprises 0.7% of IFG Advisory LLC’s portfolio, making the stock its 29th largest position.

Other large investors also recently bought and sold shares of the company. Harding Loevner LP bought a new stake in Johnson & Johnson in the 2nd quarter worth approximately $106,000. IHT Wealth Management LLC grew its position in Johnson & Johnson by 46.4% in the 2nd quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock worth $122,000 after purchasing an additional 3,467 shares during the period. Mountain Capital Investment Advisors Inc bought a new stake in Johnson & Johnson in the 2nd quarter worth approximately $124,000. Cerebellum GP LLC bought a new stake in Johnson & Johnson in the 4th quarter worth approximately $166,000. Finally, Lenox Wealth Management Inc. grew its position in Johnson & Johnson by 1.7% in the 2nd quarter. Lenox Wealth Management Inc. now owns 1,457 shares of the company’s stock worth $193,000 after purchasing an additional 24 shares during the period. 67.18% of the stock is owned by institutional investors and hedge funds.

A number of equities research analysts have recently issued reports on JNJ shares. Wells Fargo reissued an “outperform” rating and set a $160.00 price objective (up previously from $155.00) on shares of Johnson & Johnson in a research report on Friday, January 12th. Vetr raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $150.89 price objective for the company in a research report on Thursday, January 11th. Credit Suisse Group set a $154.00 price objective on shares of Johnson & Johnson and gave the company a “hold” rating in a research report on Monday, January 22nd. Royal Bank of Canada reissued a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, January 9th. Finally, BTIG Research reissued a “sell” rating and set a $110.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, January 24th. Five analysts have rated the stock with a sell rating, eight have given a hold rating and ten have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $142.23.

Shares of Johnson & Johnson stock opened at $128.27 on Friday. The firm has a market capitalization of $340,084.69, a P/E ratio of 17.57, a PEG ratio of 1.94 and a beta of 0.74. The company has a quick ratio of 1.12, a current ratio of 1.41 and a debt-to-equity ratio of 0.51. Johnson & Johnson has a fifty-two week low of $122.15 and a fifty-two week high of $148.32.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, April 17th. The company reported $2.06 earnings per share for the quarter, topping the consensus estimate of $2.00 by $0.06. The company had revenue of $20.01 billion during the quarter, compared to the consensus estimate of $19.50 billion. Johnson & Johnson had a net margin of 1.58% and a return on equity of 30.05%. Johnson & Johnson’s quarterly revenue was up 12.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.83 EPS. sell-side analysts forecast that Johnson & Johnson will post 8.13 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 12th. Investors of record on Tuesday, May 29th will be issued a $0.90 dividend. The ex-dividend date of this dividend is Friday, May 25th. This represents a $3.60 annualized dividend and a yield of 2.81%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $0.84. Johnson & Johnson’s dividend payout ratio is currently 46.03%.

In related news, VP Paulus Stoffels sold 155,342 shares of the company’s stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $129.86, for a total value of $20,172,712.12. Following the completion of the transaction, the vice president now owns 357,906 shares of the company’s stock, valued at approximately $46,477,673.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.22% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.